PPARA and cancer: This advantageous renal effect of PPAR activators along with their capacity to enhance the growth inhibitory effect of cisplatin [12] and offset the development of cancer chemoresistance [62] might boost the anticipated benefits of using these drugs along with cisplatin in clinical practice.